Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of mesdopetam for troublesome dyskinesia in Parkinson's disease
MOH_2021-02-10_009741Phase 2Completed
- Sponsor
- IRLAB
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesdopetam in Parkinson's disease (PD) (4 arms), sponsored by IRLAB. Primary endpoint: Change in daily ON time without troublesome dyskinesia. Started Oct 2020; status: completed.
02
Drugs
mesdopetam
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2021-02-10_009741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-10_009741.